Norges Bank’s Nektar Therapeutics NKTR Stock Holding History

Norges Bank’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$2.11M	–	911
2025 Q4	$2.11M	Buy	+50,000	New	+$2.8M	﹤0.01%	1451
2023 Q4	–	Sell	-17,431	Closed	-$156K	–	1986
2023 Q3	$156K	Hold	17,431	–	–	﹤0.01%	1954
2023 Q2	$150K	Hold	17,431	–	–	﹤0.01%	1998
2023 Q1	$184K	Sell	17,431 -95,692	-85%	-$2.9M	﹤0.01%	2076
2022 Q4	$3.83M	Hold	113,123	–	–	﹤0.01%	1849
2022 Q3	$5.43M	Hold	113,123	–	–	﹤0.01%	1738
2022 Q2	$6.45M	Buy	113,123 +6,748	+6%	+$426K	﹤0.01%	1705
2022 Q1	$8.6M	Sell	106,375 -11,453	-10%	-$1.7M	﹤0.01%	1749
2021 Q4	$23.9M	Buy	117,828 +22,373	+23%	+$4.85M	﹤0.01%	1380
2021 Q3	$25.7M	Sell	95,455 -25,378	-21%	-$6.1M	0.01%	1329
2021 Q2	$31.1M	Sell	120,833 -2,813	-2%	-$779K	0.01%	1248
2021 Q1	$37.1M	Sell	123,646 -22,434	-15%	-$6.98M	0.01%	1149
2020 Q4	$37.3M	Hold	146,080	–	–	0.01%	1174
2020 Q3	$36.4M	Sell	146,080 -10,320	-7%	-$3.25M	0.01%	1024
2020 Q2	$54.3M	Sell	156,400 -5,734	-4%	-$1.79M	0.02%	781
2020 Q1	$43.4M	Hold	162,134	–	–	0.02%	771
2019 Q4	$52.5M	Sell	162,134 -3,366	-2%	-$976K	0.01%	878
2019 Q3	$45.2M	Buy	165,500 +13,476	+9%	+$4.94M	0.01%	928
2019 Q2	$81.1M	Buy	152,024 +22,783	+18%	+$11.4M	0.03%	609
2019 Q1	$65.1M	Hold	129,241	–	–	0.02%	699
2018 Q4	$63.7M	Buy	129,241 +15,370	+13%	+$9.28M	0.02%	613
2018 Q3	$104M	Buy	113,871 +4,323	+4%	+$3.69M	0.03%	480
2018 Q2	$80.2M	Buy	109,548 +15,828	+17%	+$18.3M	0.03%	576
2018 Q1	$149M	Sell	93,720 -67,933	-42%	-$87.5M	0.05%	341
2017 Q4	$145M	Sell	161,653 -19,261	-11%	-$11.4M	0.05%	352
2017 Q3	$65.1M	Hold	180,914	–	–	0.02%	632
2017 Q2	$53.1M	Buy	180,914 +24,092	+15%	+$6.96M	0.02%	703
2017 Q1	$55.2M	Sell	156,822 -14,730	-9%	-$3.31M	0.02%	654
2016 Q4	$31.6M	Buy	171,552 +18,105	+12%	+$3.68M	0.01%	976
2016 Q3	$37.8M	Hold	153,447	–	–	0.02%	789
2016 Q2	$32.8M	Hold	153,447	–	–	0.02%	874
2016 Q1	$31.6M	Buy	153,447 +11,167	+8%	+$2.14M	0.02%	875
2015 Q4	$36M	Hold	142,280	–	–	0.02%	780
2015 Q3	$23.4M	Hold	142,280	–	–	0.01%	1029
2015 Q2	$26.7M	Hold	142,280	–	–	0.01%	1009
2015 Q1	$23.5M	Buy	142,280 +28,935	+26%	+$5.95M	0.01%	1107
2014 Q4	$26.4M	Buy	113,345 +34,373	+44%	+$7.35M	0.01%	1035
2014 Q3	$14.3M	Sell	78,972 -46,107	-37%	-$8.82M	0.01%	1367
2014 Q2	$24.1M	Buy	125,079 +62,539	+100%	+$11.1M	0.01%	1527
2014 Q1	$11.4M	Hold	62,540	–	–	0.01%	1516
2013 Q4	$10.6M	Sell	62,540 -573	-0.9%	-$92.4K	0.01%	1537
2013 Q3	$9.89M	Buy	63,113 +11,802	+23%	+$2.18M	0.01%	1571
2013 Q2	$8.89M	Buy	+51,311	New	+$7.87M	0.01%	1546

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank's NKTR Position: Q1 2026 in Review

Norges Bank sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 50,000 shares — an estimated $2.11M sold.

Norges Bank first reported a position in NKTR in Q2 2013 and held it in 43 quarters. The position peaked at $149M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Norges Bank reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 50,000 Nektar Therapeutics shares in Q1 2026, an estimated $2.11M.
Norges Bank first reported a position in Nektar Therapeutics in Q2 2013 and held it in 43 quarters.
Norges Bank's Nektar Therapeutics position peaked at $149M in Q1 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.